How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

297 results for

adhd Bupropion

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents

, Ph.D. AHRQ Publication No. 18-EHC005-EF January 2018 ii Key Messages Purpose of Review To update a previous review by comparing strategies to diagnose, treat, and monitor children and adolescents with attention deficit hyperactivity disorder (ADHD). Key Messages • Evidence was insufficient on imaging or electroencephalogram to diagnose ADHD in children 7–17 years of age. • Little evidence adds to the 2011 report that found that methylphenidate is effective for children under age 6 with ADHD (...) . Harvard TH Chan School of Public Health Boston, MA Peter Jensen, M.D. Mayo Clinic Rochester, MN viii Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents Structured Abstract Objectives. Attention deficit hyperactivity disorder (ADHD) is a common pediatric neurobehavioral disorder often treated in the primary care setting. This systematic review updates and extends two previous Agency for Healthcare Research and Quality (AHRQ) systematic evidence reviews

2018 Effective Health Care Program (AHRQ)

2. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release

in March 2016. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Guanfacine prolonged-release (Intuniv) is a non-stimulant treatment for children and young people with attention deficit hyperactivity disorder (ADHD). In 3 short-term, randomised controlled trials (RCTs) it was more effective than placebo at improving ADHD symptoms, although a beneficial effect on social functioning (...) February 2016). Atomoxetine 4 mg/ml oral solution (Strattera) costs £23.33–£233.33 for 28 days treatment at a dose of 10–100 mg daily (excluding VAT; Drug T ariff, February 2016). Introduction and current guidance Attention deficit hyperactivity disorder (ADHD) is a heterogeneous behavioural syndrome characterised by the core symptoms of hyperactivity, impulsivity and inattention. The NICE guideline on ADHD (currently being updated, publication expected January 2018) covers diagnosing and managing ADHD

2016 National Institute for Health and Clinical Excellence - Advice

3. Attention deficit hyperactivity disorder in children and young people: clonidine

Behavior Disorders"/ (20051) 22 (hyperactiv* or adhd or "attention deficit").ab,ti. (36749) 23 21 or 22 (42937) Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 26 of 2924 Clonidine/ (12346) 25 (clonidine or clon-ir or clon-xr or catapres).tw. (13055) 26 24 or 25 (16313) 27 23 and 26 (449) 28 14 and 27 (15) 29 19 and 27 (69) 30 28 (...) ), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Clonidine is an alpha 2 -adrenergic agonist that is licensed in the UK for adults to prevent migraine, prevent hot flushing associated with menopause, and treat hypertension. It does not have a UK licence to treat attention deficit hyperactivity disorder (ADHD) in any age group. It is sometimes used off-label (generally as an add-on to a licensed psychostimulant medicine, such as methylphenidate) to treat ADHD

2013 National Institute for Health and Clinical Excellence - Advice

4. Transcranial Magnetic Stimulation for Attention Deficit/Hyperactivity Disorder (ADHD)

a U.S. FDA-regulated Device Product: Yes Device Product Not Approved or Cleared by U.S. FDA: No Pediatric Postmarket Surveillance of a Device Product: No Keywords provided by University of Pennsylvania: ADHD TMS Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs (...) Transcranial Magnetic Stimulation for Attention Deficit/Hyperactivity Disorder (ADHD) Transcranial Magnetic Stimulation for Attention Deficit/Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2018 Clinical Trials

5. Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Amphetamine Central Nervous System Stimulants Physiological Effects of Drugs Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents (...) Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2018 Clinical Trials

6. Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: A Review of the Clinical Evidence

age 43) (cross-over study) Randomized, double- blind, placebo- controlled, cross-over study 6 weeks Improvement in ADHD symptoms measured by the DSM-IV ADHD Behavior Checklist for Adults, the Controlled Oral Word Association Test (COWAT), Stroop and Digit Span Safety (adverse effects) ADHD: attention-deficit/hyperactivity disorder; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders (4 th edition) Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for ADHD 12 Appendix 3 (...) by the owners’ own terms and conditions. TITLE: Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: A Review of the Clinical Evidence DATE: 21 March 2013 CONTEXT AND POLICY ISSUES Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder with inappropriate levels of inattention, hyperactivity, and impulsivity manifesting in childhood and continuing into adulthood, resulting in functional

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Device Product: No Keywords provided by Sunovion: Attention-Deficit Hyperactivity Disorder (ADHD) Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2017 Clinical Trials

8. Attention-Deficit Hyperactivity Disorder

Attention-Deficit Hyperactivity Disorder 1 Quality Department Guidelines for Clinical Care Ambulatory ADHD Guideline Team Team Leaders John M O'Brien, MD Family Medicine Jennifer G. Christner, MD Child Behavioral Health Team Members Bernard Biermann, MD, PhD Child/Adolescent Psychiatry Barbara T Felt, MD Child Behavioral Health R Van Harrison, PhD Medical Education Paramjeet K Kochhar, MD General Pediatrics Consultant Darcie-Ann Streetman, PharmD College of Pharmacy Initial Release August, 2005 (...) of child’s self-identified impression of function, both strengths and weaknesses • Clinician’s observations of child’s behavior • Physical and neurologic examination Note: From ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents, American Academy of Pediatrics, Nov. 2011 Table 4. Treatment Options for ADHD For pre-school aged children, first line is behavior therapy. If not significantly improved, prescribe

2013 University of Michigan Health System

9. Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults [Cochrane protocol]

Bupropion for Attention Deficit Hyperactivity Disorder (ADHD) in adults [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

10. Group Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/Hyperactive Disorder

Hyperactive Disorder Skill Training Group Dialectical Behavior Therapy Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) Group Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/Hyperactive Disorder Group Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/Hyperactive Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2017 Clinical Trials

11. Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder Full Text available with Trip Pro

Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder Our study is an analysis of multiple publications involving assessing the comparable efficacy and tolerability of six interventions, which are lisdexamfetamine dimesylate (LDX), atomoxetine (ATX), methylphenidate (MPH), clonidine hydrochloride (CLON), guanfacine extended release (GXR), and bupropion, for young patients (6-18 years old) suffering from attention deficit (...) hyperactivity disorder (ADHD).A conventional meta-analysis (MA) was performed to give direct comparisons and a network meta-analysis (NMA) was used to show the combination of direct and indirect evidence. Ranking preference for all the interventions under a certain outcome was given by the surface of cumulative ranking curve area (SUCRA).Overall, 15,025 participants from 73 studies were involved in our analysis. In the pairwise MA, LDX was associated with less withdrawal than ATX for lack of efficacy. MPH

2017 Frontiers in Psychiatry

12. A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

: Other Study ID Numbers: SEP360-305 First Posted: April 12, 2016 Last Update Posted: January 10, 2018 Last Verified: January 2018 Keywords provided by Sunovion: Attention-Deficit Hyperactivity Disorder (ADHD) Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous (...) A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2016 Clinical Trials

13. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse

health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions RCTs examining the efficacy of bupropion in adult ADHD frequently reported (...) Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published

2010 Health Technology Assessment (HTA) Database.

14. Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study. (Abstract)

Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study. Attention-Deficit/Hyperactivity Disorder is one of the most common mental disorders in childhood, and it continues to adulthood without proper treatment. Stimulants have been used in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) for many years, and the efficacy of methylphenidate in the treatment of adults with ADHD has been proven to be acceptable according to meta-analysis (...) studies. However, there are some concerns about stimulants. Finding other effective medications for the treatment of adult ADHD seems necessary. We hypothesized bupropion could be effective in the treatment of adult ADHD because some theoretical and experimental evidence exists to support efficacy of this medication. Forty-two patients with a diagnosis of ADHD, according to the revised fourth edition of the Diagnostic and Statistical Manual of Mental Disorders, were randomized to receive 150 mg/day

2014 Acta medica Iranica Controlled trial quality: uncertain

15. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. (Abstract)

Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. To compare the safety and efficacy of bupropion with methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).In a 6-week randomized double-blind study, 44 patients with a DSM-IV-TR diagnosis of ADHD were randomly assigned to receive bupropion 100-150 mg/day (100 mg/day for <30 kg and 150 mg/day for >30 kg (...) ) or methylphenidate 20-30 mg/day. Symptoms were assessed using Teacher and Parent Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) at baseline and weeks 3 and 6.Forty patients had at least one post-baseline measurement, and 38 patients completed the trial. No significant difference was found between the two groups on the Parent and Teacher ADHD-RS-IV scores ([F(1, 38) = 0.266, p = 0.609] and [F(1, 38) = 0.001, p = 0.972], respectively). By week 6, 18 patients (90%) in each group achieved

2012 Human psychopharmacology Controlled trial quality: uncertain

16. Attention Deficit Hyperactivity Disorder (Treatment)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjg5MzUwLXRyZWF0bWVudA== processing > Attention Deficit Hyperactivity Disorder (ADHD) Treatment & Management Updated: Dec 26, 2018 Author: Stephen Soreff, MD; Chief Editor: Glen L Xiong, MD Share Email Print Feedback Close Sections Sections Attention Deficit Hyperactivity Disorder (ADHD) Treatment Medical Care The therapeutic approach to ADHD has been shifting. In some cases, environmental restructuring and behavioral therapy alone has been effective. Developments in behavioral parent training (BPT) and behavioral (...) Attention Deficit Hyperactivity Disorder (Treatment) Attention Deficit Hyperactivity Disorder (ADHD) Treatment & Management: Medical Care, Diet, Activity Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache

2014 eMedicine.com

17. An Exploratory, Single-Blind Pilot Study Of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

: Neurovance, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: EB-1020-SR-ADHD-201 First Posted: September 11, 2013 Last Update Posted: November 5, 2015 Last Verified: September 2015 Keywords provided by Euthymics BioScience, Inc. ( Neurovance, Inc. ): Adult ADHD Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders (...) Comparator: Placebo Matching Placebo Drug: Matching Placebo Outcome Measures Go to Primary Outcome Measures : Change from Baseline-2 in Attention-Deficit Hyperactivity Disorder (ADHD) symptoms to Week 4 after investigational product administration, as assessed by the adult Attention-Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) [ Time Frame: Baseline-2 and Week 4 ] Change in ADHD symptoms from Baseline-2 (after one week of placebo treatment) to Week 4 as assessed by the ADHD-RS-IV total score

2013 Clinical Trials

18. Adult Attention Deficit Hyperactivity Disorder

: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) Summary: A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD). Condition or disease Intervention/treatment Phase Adult Attention Deficit Hyperactivity Disorder Drug: SEP-225289 Drug: Placebo Phase 2 Detailed Description: This is a Phase 2, randomized, double-blind, parallel-group, multicenter, outpatient study evaluating the efficacy and safety of SEP 225289 in adults with ADHD using 2 oral dosages (4 or 8 mg SEP 225289 once daily [QD]) versus placebo over a 4

2012 Clinical Trials

19. Attention-Deficit/Hyperactivity Disorder (ADD, ADHD)

of inattention, hyperactivity, and impulsivity. The 3 types of ADHD are predominantly inattentive, predominantly hyperactive/impulsive, and combined. Diagnosis is made by clinical criteria. Treatment usually includes drug therapy with stimulant drugs, behavioral therapy, and educational interventions. Attention-deficit/hyperactivity disorder is considered a neurodevelopmental disorder. Neurodevelopmental disorders are neurologically based conditions that appear early in childhood, typically before school (...) comorbid behavior disorders, particularly and , are common. ADHD affects an estimated 8 to 11% of school-aged children ( ). However, many experts think ADHD is overdiagnosed, largely because criteria are applied inaccurately. According to the Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM-5), there are 3 types: Overview of Attention-Deficit/Hyperactivity Disorder (ADHD) VIDEO Predominantly inattentive Predominantly hyperactive/impulsive Combined Overall, ADHD is about twice

2013 Merck Manual (19th Edition)

20. Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults

, 2011 Results First Posted: February 25, 2011 Last Update Posted: March 8, 2013 Last Verified: March 2013 Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Substance-Related Disorders Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Chemically-Induced Disorders Bupropion (...) Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>